Pure Tubular Breast Carcinoma: Clinicopathological Characteristics and Clinical Outcomes.
Pure tubular breast carcinoma
and clinical outcomes
axillary lymph node metastasis
clinicopathologic characteristics
Journal
European journal of breast health
ISSN: 2587-0831
Titre abrégé: Eur J Breast Health
Pays: Turkey
ID NLM: 101709357
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
04
01
2023
accepted:
09
02
2023
medline:
8
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
Tubular breast carcinoma (TBC) is a rare subtype of breast carcinoma (BC) with a good prognosis. In this study, we aimed to assess the clinicopathological characteristics of pure TBC (PTBC), analyze factors that may influence long-term prognosis, examine the frequency of axillary lymph node metastasis (ALNM), and discuss the need for axillary surgery in PTBC. Fifty-four Patients diagnosed with PTBC between January 2003 and December 2020 at Istanbul Faculty of Medicine were included. Clinicopathological, surgical, treatment, and overall survival (OS) data were analyzed. A total of 54 patients with a mean age of 52.2 years were assessed. The mean size of the tumor was 10.6 mm. Four (7.4%) patients had not undergone axillary surgery, while thirty-eight (70.4%) had undergone sentinel lymph node biopsy and twelve (22.2%) had undergone axillary lymph node dissection (ALND). Significantly, four (33.3%) of those who had undergone ALND had tumor grade 2 ( PTBC is associated with favorable prognosis, good clinical outcomes and high survival rate, with rare recurrences and metastases.
Identifiants
pubmed: 37025580
doi: 10.4274/ejbh.galenos.2023.2022-12-9
pii: 59078
pmc: PMC10071886
doi:
Types de publication
Journal Article
Langues
eng
Pagination
115-120Informations de copyright
©Copyright 2023 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
Am J Surg. 2009 May;197(5):674-7
pubmed: 18789411
ANZ J Surg. 2015 Jun;85(6):448-51
pubmed: 25060384
Ann Surg. 1981 Feb;193(2):138-49
pubmed: 7469549
ANZ J Surg. 2001 Jan;71(1):27-31
pubmed: 11167594
Am J Surg Pathol. 2008 Apr;32(4):513-23
pubmed: 18223478
Ann Surg. 1996 Mar;223(3):342-7
pubmed: 8604915
Breast J. 2003 Jul-Aug;9(4):298-301
pubmed: 12846864
Am J Clin Pathol. 1978 Aug;70(2):204-10
pubmed: 696679
Am J Surg Pathol. 1982 Jul;6(5):401-11
pubmed: 6289683
J Clin Oncol. 2010 Jan 1;28(1):99-104
pubmed: 19917872
J Surg Oncol. 2018 May;117(6):1137-1143
pubmed: 29205352
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Br J Surg. 2001 Jun;88(6):860-4
pubmed: 11412259
Am J Clin Pathol. 1982 Jul;78(1):1-7
pubmed: 6285690
Breast J. 1999 Jul;5(4):252-255
pubmed: 11348296
Cancer. 1978 Nov;42(5):2334-42
pubmed: 214219
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722
pubmed: 35714673
Front Oncol. 2021 Apr 29;11:653388
pubmed: 33996576
Breast J. 2021 Sep;27(9):691-699
pubmed: 34173285
J Clin Oncol. 1999 May;17(5):1442-8
pubmed: 10334529
Eur J Surg Oncol. 2013 Mar;39(3):248-54
pubmed: 23273874